Delivery Order SPE2DB25D3109-SPE2DB25FPLBC
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,819.81 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen (semaglutide injection) on August 25, 2025, with completion scheduled for August 26, 2025. This is a firm fixed price, non-set-aside contract with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $20,839.40 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on August 12, 2025, with completion scheduled for August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, which serves as the company's corporate...
- The Defense Logistics Agency awarded a $35,358.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injections. The contract, designated as a non-set-aside competitive award, calls for completion by August 18, 2025, with performance at the contractor's location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, valued at $14,972.31 under firm fixed-price terms. The contract is scheduled for completion by August 19, 2025, with performance to be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside competitive award and is issued as a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a ceiling value of $1,525.20. This firm fixed-price delivery order is scheduled for completion by August 1, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a non-set-aside competitive procurement under the company's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $1,306.78 delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injectors. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 2, 2025, and performance to be executed at the vendor's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $31,248.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections on August 20, 2025, with completion targeted for August 21, 2025. This delivery order is issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $19,637.21 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 ml pens on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $15,204.28 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 21, 2025. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its primary...
- The Defense Logistics Agency awarded a delivery order valued at $5,762.72 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injectors on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under the company's existing...
- SPE2DB25D3109Indefinite Delivery Contract
- SPE2DB25D3109-SPE2DB25FPLBCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $12,468.03 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. The contract was awarded on August 28, 2025, with an ultimate completion date of August 29, 2025, under firm fixed pricing terms with no set-aside designation. Performance will take place at the vendor's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through its extensive portfolio of brand-name and generic medications, vaccines, and medical supplies. The company's competitive award reflects its capability to meet federal procurement requirements and supply diverse pharmaceutical products to support military healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. Zepbound is a glucagon-like peptide-1 (GLP-1) receptor agonist used for weight management, aligning with the company's demonstrated history of supplying specialty medications and diabetes-related therapeutics to federal customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.5k | 8/28/25 |